Johnson & Johnson presented new data on IMAAVY (nipocalimab-aahu) showing sustained disease control, improved daily function and muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG) through two years of treatment. In the Phase 2/3 Vibrance-MG long-term extension, seven adolescents were enrolled, with available participants showing mean improvements of 2.88 points in MG-ADL and 8.25 points in QMG at Week 108 compared with baseline. Additional retrospective data from healthcare providers found that fluctuating symptom control was the most commonly reported reason for switching from previous advanced therapies, although the company notes that the survey was retrospective and may be affected by reporting and recall bias.
